PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 215/42, A61K 31/47, 31/505, C07D 405/12, 239/94, 403/12, 401/04, 401/12, 239/95, 403/04, 471/04, 491/04, 497/04

A1

(11) International Publication Number: WO 97/23462

(43) International Publication Date: 3 July 1997 (03.07.97)

(21) International Application Number: PCT/EP96/05609

(22) International Filing Date: 5 December 1996 (05.12.96)

(30) Priority Data:
9526546.8 23 December 1995 (23.12.95) GB

(71) Applicant *(for all designated States except GB JP US)*: PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. [BE/IE]; La Touche House, International Financial Services Centre, Dublin 1 (IE).

(71) Applicant *(for GB only)*: PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant *(for JP only)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, N.Y. 10017 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: COLLIS, Alan, John [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). FOX, David, Nathan, Abraham [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). NEWMAN, Julie [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: HAYLES, James, Richard et al.; Pfizer Limited, European Patents Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).


(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, HU, IL, IS, JP, KR, KZ, LK, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY

(57) Abstract

The invention provides compounds of formula (I), wherein R^1 represents C_{1-4} alkoxy optionally substituted by one or more fluorine atoms; R^2 represents H or C_{1-6} alkoxy optionally substituted by one or more fluorine atoms; R^3 represents one or more groups independently selected from H, halogen, C_{1-4} alkoxy and CF_3; in addition, R^2 and one R^3 group may together represent $-OCH_2-$, the methylene group being attached to the ortho-position of the pendant phenyl ring; R^4 represents a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent or represents a cyclic group or an open chain group; and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of *inter alia* benign prostatic hyperplasia.



(I)